The efficacy of co-targeting Yap1 in PDAC cells and Cox2 in fibroblasts in vitro and in late-stage PDACs in vivo (Fig. 1h–k) highlight the codependent functions of Yap1 activation in cancer cells and of Cox2 upregulation in PSCs/fibroblasts in the Gem resistance of 14-3-3ζ+++ PDACs. Here, YAP1 is linked to cancer.